Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD

about

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD

Item

http://www.wikidata.org/entity/Q59136513

description

scientific article published on 06 November 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Future Perspectives on GLP-1 R ...... ists in the Treatment of NAFLD

@en

Future Perspectives on GLP-1 R ...... ists in the Treatment of NAFLD

@nl

type

Item

label

Future Perspectives on GLP-1 R ...... ists in the Treatment of NAFLD

@en

Future Perspectives on GLP-1 R ...... ists in the Treatment of NAFLD

@nl

prefLabel

Future Perspectives on GLP-1 R ...... ists in the Treatment of NAFLD

@en

Future Perspectives on GLP-1 R ...... ists in the Treatment of NAFLD

@nl

P1476

Future Perspectives on GLP-1 R ...... ists in the Treatment of NAFLD

@en

P2093

Alexander S Christensen

http://www.w3.org/2001/XMLSchema#string

Anna Solini

http://www.w3.org/2001/XMLSchema#string

Marta Seghieri

http://www.w3.org/2001/XMLSchema#string

Tina Vilsbøll

http://www.w3.org/2001/XMLSchema#string

P2860

Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism

Pharmacology, physiology, and mechanisms of incretin hormone action

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

Incretin mimetics as a novel therapeutic option for hepatic steatosis

Molecular mediators of hepatic steatosis and liver injury

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.

P304

649

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FENDO.2018.00649

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Filip K Knop

Andreas Andersen

P577

2018-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30459715

http://www.w3.org/2001/XMLSchema#string

P932

6232120

http://www.w3.org/2001/XMLSchema#string